|
Left Ventricular Hypertrophy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We investigated whether the angiotensin II type 1 receptor (AT1-R) A/C1166 polymorphism, the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism, and/or plasma renin influence LVH in HCM.
|
9822439 |
1998 |
|
Left Ventricular Hypertrophy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Left ventricular hypertrophy in patients with hypertension is a main clinical prognostic entity The aim of this study was to evaluate the association between mutations at genes of the renin-angiotensin system (RAS) and the development of left ventricular hypertrophy.
|
12425365 |
2002 |
|
Left Ventricular Hypertrophy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of the renin-angiotensin-aldosterone system (RAAS) have been considered to trigger the response of the left ventricle to chronic pressure overload and determine the degree of LVH in patients with AS.
|
11275936 |
2001 |
|
Left Ventricular Hypertrophy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The cardiac renin-angiotensin system has been suggested to be involved in the development of left ventricular hypertrophy.
|
7994801 |
1994 |
|
Left Ventricular Hypertrophy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Subsequent treatment with cilazapril significantly improved LV morphology and function in those with residual LV hypertrophy or elevated plasma renin activity.
|
10937840 |
2000 |
|
Left Ventricular Hypertrophy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Untreated transgenic rats overexpressing the human renin and angiotensinogen genes (dTGR) feature hypertension and severe left ventricular hypertrophy with focal areas of necrosis, and die at age 7 weeks.
|
10880382 |
2000 |
|
Left Ventricular Hypertrophy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis.
|
29465713 |
2018 |
|
Left Ventricular Hypertrophy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Both the activation of the renin angiotensin aldosterone system (RAAS) and elevations of circulating Fibroblast Growth Factor-23 (FGF-23) have been implicated in the pathogenesis of left ventricular hypertrophy (LVH) in chronic kidney disease.
|
30120363 |
2018 |
|
Left Ventricular Hypertrophy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To determine the influence of genetic polymorphisms of the renin-angiotensin-aldosterone system (RAAS) on ECG and two dimensional echocardiographic left ventricular hypertrophy (LVH) in genetically identical patients with HCM.
|
11847170 |
2002 |
|
Left Ventricular Hypertrophy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Being a major contributor to the development of diastolic heart dysfunction, the renin angiotensin aldosterone system and its genetic variations are thought to induce LVH in hypertensive hearts apart from haemodynamic factors.
|
26861937 |
2016 |
|
Left Ventricular Hypertrophy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In hypertension the 825T allele is associated with low renin activity and appears to strongly predict the development of left ventricular hypertrophy.
|
10978382 |
2000 |
|
Left Ventricular Hypertrophy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We investigated the role of three renin-angiotensin-aldosterone system (RAAS) gene polymorphisms in the development of LVH in hypertensive patients with a diagnosis of HFpEF.
|
28513230 |
2017 |
|
Left Ventricular Hypertrophy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of the renin-angiotensin-aldosterone system (RAAS) represent an attractive hypothesis as potential disease modifiers, as these genetic variants alter the 'activation status' of the RAAS, which leads to more left ventricular hypertrophy through different pathways.
|
21507890 |
2011 |
|
Left Ventricular Hypertrophy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Enalapril-induced regression of left ventricular hypertrophy and improvement in left ventricular impaired diastolic filling were significantly greater in the DD genotype group than they were in the ID and II genotype groups, suggesting that the circulating and tissue renin-angiotensin systems, particularly the former system, are most active in hypertensive patients with the DD genotype.
|
8986921 |
1996 |
|
Left Ventricular Hypertrophy
|
0.600 |
Biomarker
|
disease |
CTD_human |
Systolic blood pressure, plasma renin activity, and cardiac angiotensin converting enzyme activity of L-NAME rats with left ventricular hypertrophy were significantly higher than those of the subgroup without.(ABSTRACT TRUNCATED AT 250 WORDS)
|
8349331 |
1993 |
|
Left Ventricular Hypertrophy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensinogen (AGT), the precursor of angiotensin II and a rate limiting factor in the renin-angiotensin system, is implicated in left ventricular hypertrophy, as angiotensin II is a potent stimulator of cardiac growth.
|
16280278 |
2005 |
|
Left Ventricular Hypertrophy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The association of renin-angiotensin system (RAS) polymorphisms and left-ventricular hypertrophy (LVH) may depend on the presence of risk factors for LVH, such as renal dysfunction.
|
17903694 |
2007 |
|
Left Ventricular Hypertrophy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We conclude that, in this population, variations in the renin or ACE genes do not contribute significantly to the development of LVH or to essential hypertension.
|
8076423 |
1994 |
|
Left Ventricular Hypertrophy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In the light of these observations it seems reasonable to make a preliminary conclusion about lack of association between LVH and distinct polymorphisms of renin-angiotensin system genes in the population studied.
|
11688760 |
2001 |
|
Left Ventricular Hypertrophy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Renin-angiotensin system gene polymorphisms and left ventricular hypertrophy. The case against an association.
|
9433518 |
1997 |
|
Left Ventricular Hypertrophy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The renin-angiotensin system (RAS) is involved in the development of left ventricular hypertrophy (LVH) by which increases cardiac morbidity and mortality.
|
28160636 |
2017 |
|
Left Ventricular Hypertrophy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Activation of the local renin-angiotensin system (RAS) is an independent risk factor for the development of proteinuria and left ventricular hypertrophy (LVH) more commonly seen in masked hypertensives.
|
30080282 |
2018 |
|
Left Ventricular Hypertrophy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Existing data show that the renin-angiotensin-aldosterone (RAA) system may play a role in the development of LVH.
|
17054027 |
2006 |
|
Left Ventricular Hypertrophy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Myocardial fibrosis in patients with symptomatic obstructive hypertrophic cardiomyopathy: correlation with echocardiographic measurements, sarcomeric genotypes, and pro-left ventricular hypertrophy polymorphisms involving the renin-angiotensin-aldosterone system.
|
18835191 |
2009 |
|
Left Ventricular Hypertrophy
|
0.600 |
Biomarker
|
disease |
BEFREE |
In patients with aortic stenosis, genetic variants of proteins from the renin angiotensin system may be at least as important as left ventricular systolic pressure in determining the degree of left ventricular hypertrophy and could therefore explain the clinical variation observed in the progression to cardiac dysfunction.
|
8800593 |
1996 |